BRPI0506550A - uso do metronidazol para a preparação de uma composição farmacêutica - Google Patents

uso do metronidazol para a preparação de uma composição farmacêutica

Info

Publication number
BRPI0506550A
BRPI0506550A BRPI0506550-0A BRPI0506550A BRPI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A
Authority
BR
Brazil
Prior art keywords
metronidazole
preparation
pharmaceutical composition
receptor
pac
Prior art date
Application number
BRPI0506550-0A
Other languages
English (en)
Inventor
Fabrizio Dolfi
Irina Safonova
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BRPI0506550A publication Critical patent/BRPI0506550A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DO METRONIDAZOL PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA". A presente invenção trata do uso do metronidazol para a preparação de uma composição farmacêutica destinada a tratar as patologias que envolvem pelo menos um receptor escolhido no grupo que compreende o receptor IL-8RB e o receptor PAC-1.
BRPI0506550-0A 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica BRPI0506550A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
PCT/FR2005/000370 WO2005089750A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l’interleukine 8 et/ou recepteur de type 1 de pacap

Publications (1)

Publication Number Publication Date
BRPI0506550A true BRPI0506550A (pt) 2007-02-27

Family

ID=34833946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506550-0A BRPI0506550A (pt) 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica

Country Status (11)

Country Link
US (1) US20080221189A1 (pt)
EP (1) EP1718296A2 (pt)
JP (1) JP2007523133A (pt)
KR (1) KR20060124707A (pt)
CN (1) CN1921852A (pt)
AU (1) AU2005224123A1 (pt)
BR (1) BRPI0506550A (pt)
CA (1) CA2553932A1 (pt)
FR (1) FR2866569B1 (pt)
RU (1) RU2006133534A (pt)
WO (1) WO2005089750A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
CA2161737C (en) * 1995-10-30 1998-10-20 Richard J. Mackay Metronidazole gel
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
ATE384524T1 (de) * 1999-07-16 2008-02-15 Shoei Co Ltd Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
CA2524739A1 (en) * 2003-06-18 2004-12-29 Galderma S.A. Metronidazole-based green tinted topical pharmaceutical composition

Also Published As

Publication number Publication date
US20080221189A1 (en) 2008-09-11
FR2866569B1 (fr) 2007-08-24
CN1921852A (zh) 2007-02-28
JP2007523133A (ja) 2007-08-16
FR2866569A1 (fr) 2005-08-26
CA2553932A1 (fr) 2005-09-29
EP1718296A2 (fr) 2006-11-08
WO2005089750A3 (fr) 2006-05-04
WO2005089750A2 (fr) 2005-09-29
KR20060124707A (ko) 2006-12-05
RU2006133534A (ru) 2008-03-27
AU2005224123A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0817096B8 (pt) análogo de tiazolidinodiona e composição farmacêutica que o compreende
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
ECSP099071A (es) Agonistas de ep2
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]